Activation of the neu Tyrosine Kinase Induces the fos/jun Transcription Factor Complex, the Glucose Transporter, and Ornithine Decarboxylase

Lea Sistonen, Erkki Hölttä, Heikki Lehväslaiho, Laura Lehtola, and Kari Alitalo

Departments of Virology and Pathology, University of Helsinki, 00290 Helsinki 29, Finland

Abstract. We have studied the ability of the neu tyrosine kinase to induce a signal for the activation of cell growth-regulated genes. Serum-starved NIH 3T3 cells expressing an epidermal growth factor receptor (EGF-R)/neu construct encoding a hybrid receptor protein were stimulated with EGF and the activation of the neu tyrosine kinase and stimulation of growth factor inducible genes were followed at the mRNA, protein, and activity levels, and compared to the corresponding responses in the neu proto-oncogene and oncogene expressing cells. Induction of the expression of jun mRNAs was an immediate early effect of EGF stimulation, followed by a marked increase in the biosynthesis of the fos/jun transcription factor complex and an increased transcription factor activity as measured by a recombinant transcription unit using chloramphenicol acetyltransferase assays. In distinction, elevated AP-1/PEA-1 activity in the absence of a significant increase in jun and fos expression was characteristic of the neu oncogene-expressing cells. The glucose transporter mRNA increased at 2 h of EGF stimulation and was associated with enhanced glucose transport of the EGF-treated cells. An increase of ornithine decarboxylase (ODC) mRNA and activity followed these changes. In contrast, serum-starved, EGF-treated neu proto-oncogene- and oncogene-expressing cells showed constitutively low and high glucose transporter and ODC activities, respectively. These findings demonstrate that the chimeric EGF-R/neu receptor is capable of activating the expression of both immediate early genes and biochemical activities associated with cell growth stimulation.

Quiescent cells are rendered capable of traversing the cell cycle by a cascade of events initiated by the binding of growth factors to their receptors at the cell surface and resulting in the activation of genes and biochemical activities expressed during the G1 and S phases of the cell cycle (Heldin and Westermark, 1984; Lau and Nathans, 1987; Almendral et al., 1988). However, growth factors differ in their effects on different cells. They can be classified into at least two categories, called the competence and progression factors, depending on whether they are sufficient for the transfer of stimulated cells from a quiescent state (G0) back to the cell cycle or whether they are required later, during cell progression into the S phase (Harrington and Pledger, 1987). This specificity of growth factor action is determined by the specific growth factor receptors, their effector functions, signal transduction mechanisms, and substrates, which are reflected at the genomic level in the activation of cell- and growth factor-specific gene responses. Oncogenes can deregulate signal transduction mechanisms and growth factor inducible genes at various levels and prevent cells from entering a quiescent stage.

The biochemical mechanisms of signal transduction used by many growth factor receptors remain uncharacterized in the absence of known ligands for several growth factor receptor tyrosine kinases encoded by genes that have been cloned recently. Thus, the protein product of the neu oncogene has been assumed to function as a tyrosine kinase growth factor receptor because of its close homology and immunochemical similarity with the epidermal growth factor receptor (EGF-R)1 (Schechter et al., 1984; Bargmann et al., 1986a). Consistent with this idea, the rat neu protein, activated by a point mutation in the transmembrane domain of the putative receptor, has a tyrosine kinase activity (Bargmann et al., 1986b) as does its human homologue, the HER2/erbB2 protein, when overexpressed in NIH 3T3 cells (Hudziak et al., 1987). It is not known, however, how the function of the neu oncoprotein differs from its normal counterpart and what is the mechanism of cell transformation by the mutant protein.

We have undertaken a study of the function of the neu tyrosine kinase by expressing a chimeric EGF-R/neu protein in NIH 3T3 cells and analyzing its tyrosine kinase activity and effects in cells stimulated by EGF (Lehväslaiho et al., 1989). This study has indicated that the ligand-activated neu tyrosine kinase is capable of inducing DNA synthesis in resting

1. Abbreviations used in this paper: CAT, chloramphenicol acetyltransferase; CHX, cycloheximide; 2-DOG, 2-deoxyglucose; EGF, epidermal growth factor; EGF-R, EGF receptor; GT, glucose transporter; ODC, ornithine decarboxylase; TRE, 12-O-tetradecanoyl-phorbol-13-acetate-responsive element.
Molecular Clones

The proto-oncogene neu cDNA and SV40 polyadenylation site from plasmid pSV2neoN (Bargmann et al., 1986b) and Moloney murine leukemia virus LTR from plasmid pMP1 (Schwab et al., 1985) were joined together in pSP72 (Promega Biotec, Madison, WI) cloning vector to yield the expression vector pLTRneo.

The following cDNA clones were used as molecular probes: pODC 16 (mouse ornithine decarboxylase; Jänne et al., 1984), pGT4-12 (rat glucose-6-phosphate dehydrogenase; Fort et al., 1985). Nick translations of DNA were carried out according to the manufacturer's instructions (Amerham Corp., Arlington Heights, IL); protein A-Sepharose, acetyl coenzyme A, and chloramphenicol acetyltransferase (Echerichia coli) (Pharmacia Fine Chemicals, Uppsala, Sweden), D luciferin from Enzymatics Ltd. (Cambridge, UK), and cell culture reagents including the neomycin analogue genetinc (G418 sulphate) from Gibco Laboratories (Grand Island, NY).

Metabolic Labeling and Immunoprecipitation

For immunoprecipitation of neu and EGF-R proteins, rabbit anti-serum (Lehväsaalo et al., 1989), and mouse monoclonal antibodies against the EGF-R extracellular domain (RPN.513, Amersham Corp.) were used, respectively. The cells were metabolically labeled for 14–16 h with [3H]methionine (100 μCi/ml). Autophosphorylation of the EGF-R/neu receptor was analyzed after treatment of the metabolically labeled cells with 25 nM EGF for 2 min at room temperature after which the cells lysates were immunoprecipitated with affinity-purified antiphosphotyrosine antibodies (kindly provided by Dr. H. Fujio, Osaka University, Osaka, Japan; Seki et al., 1983). For immunoprecipitation, the cells were lysed in 0.1% SDS, 0.5% Triton X-100, 0.5% sodium deoxycholate, 20 mM Tris-HCl, pH 7.5, and sonicated for 1 min at 300 W on ice. The lysates were centrifuged for 30 min at 10,000 rpm at +4°C in a HB-4 rotor in a centrifuge (Sorvall, Newtown, CT), and the supernatant aliquote into which antibody was added and allowed to bind at 4°C for 1 h. For blocking experiments, 2 μl of antibody was preincubated with 2 μg of bacterial neu protein for 20 h. About 30 μl of a 50% vol/vol solution of protein A-sepharose (Pharmacia Fine Chemicals) was added to the antibody-containing lysates and the tubes were mixed gently for 1 h at 4°C. For immunoprecipitation of the EGF-R with mouse monoclonal antibodies, rabbit anti-mouse immunoglobulin-coated, washed protein A-Sepharose particles were used. The immune complexes were washed five times with the immunoprecipitation buffer, twice with PBS, and once with 20 mM Tris-HCl, pH 7.0, dissolved in the electrophoresis sample buffer containing 2% SDS, 5% β-mercaptoethanol, 10% glycerol, and 50 mM Tris-HCl (pH 6.8), and boiled for 5 min.

For detection of the jun and fos proteins, the cells were serum-starved in 0.5% FCS for 24 h before either EGF (3 nM) or dialyzed FCS (20%) was added to the methionine-free medium in which the cells were incubated for 30 min before methionine labeling (250 μCi/ml) for 45 min at 37°C. Immunoprecipitation of the jun protein was carried out using cell lysates preincuborled with normal rabbit serum and the rabbit polyclonal antibodies PEP-I and PEP-2 (1:1) produced against synthetic v-jun peptides (kindly provided by Dr. Peter K. Vogt; Bohmann et al., 1987). The sheep anti-c-fos peptide antibodies were from Cambridge Research Biochemicals Ltd. (Cambridge, UK) (DCP 821). The neu and EGF-R proteins were analyzed in a 7.5% SDS-PAGE and jun and fos proteins in a 10% SDS-PAGE according to the method of Laemmli (1970). After electrophoresis, the gels were fixed in 10% acetic acid, impregnated with Amplify (Amersham Corp.), dried onto filter paper, and fluorographed (X-Omat R film Eastman Kodak Co., Rochester, NY).

The Journal of Cell Biology, Volume 109, 1989
Immunoprecipitation (A) and EGF-induced tyrosine kinase activity (B) of the EGF-R, neu and chimeric EGF-R/neu growth factor receptors. A, The cells were labeled with [35S]methionine overnight and cell lysates were immunoprecipitated with rabbit antibodies against the carboxyl terminal domain of the rat neu receptor expressed in E. coli (Lehväslaiho et al., 1989) or with monoclonal anti-EGF-R antibodies as detailed in Materials and Methods. Shown is an autofluorogram of SDS-PAGE analysis of anti-neu-precipitates from the NN, NEN37, N6, and NT12 cells as well as anti-EGF-R-precipitates from the C125 cells. Note that the neu oncogene-transformed NT12 cells express smaller amounts of receptor polypeptides than the other receptor transfectants. B, After metabolic labeling overnight, the cells were stimulated with 25 nM EGF (for 2 min) or with buffer (0) and lysates were precipitated with anti-neu and antiphosphotyrosine antibodies, as shown.

**Assay for CAT Activity**

The cells were seeded at ~4 x 10^5 cells/100 mm plate and grown in medium containing 10% FCS for 24 h, after which they were changed into medium supplemented with 0.5% FCS and incubated for a further 20 h. The cells were then transfected in low-serum medium with 20 µg of plasmid DNA using the calcium phosphate precipitation method. Incubation with the DNA-precipitate was for 16 h followed by a 1 min rinse in serum-free medium containing 20% glycerol. 24 h later, EGF was added at a final concentration of 10 nM, and after 8 h the cells were harvested and the cell extracts were prepared by freezing and thawing the cells in 100 µl of 0.1 M potassium phosphate (pH 7.8), 1 mM DTT.

The CAT activity was measured essentially as described by Gorman et al. (1982). 0 µl of the cell extract was incubated at 37°C in a final volume of 180 µl together with 0.5 µCi of [14C]-chloramphenicol. After 30 min, the reaction was stopped and the chloramphenicol was extracted with 1 ml of cold ethyl acetate. 14C-labeled chloramphenicol was separated from acetylated forms by developing the silica gel thin-layer plates in chloroform-methanol (95:5; ascending). After autoradiography of the separated acetylated chloramphenicol forms, the radioactive spots were cut out and counted. The CAT activity was calculated by determining the percentage of acetylated chloramphenicol per mg protein assayed with a Protein Assay Kit (Bio-Rad Laboratories).

**Luciferase Assay**

All CAT constructs were cotransfected in ratio of 1:5 with the pRSVL plasmid. Luciferase activity of the cell extracts was analyzed essentially as described by de Wet et al. (1987). 50 µl of 40 mM ATP and 5 µl of 20 mM luciferin were added in 370 µl of 25 mM glycylglycine (pH 7.8) and 15 mM MgSO₄ containing 20 µl of the cell extract. The peak light emission was recorded with a luminometer (1250; LKB Instruments, BioOrbit, Finland).

**Results**

**Autophosphorylation of the EGF-R/neu Receptor upon EGF Stimulation**

For the studies on the effects of neu tyrosine kinase activation, we used mouse NIH 3T3 cell clones expressing an EGF-R/neu hybrid receptor protein on their surface (Lehväslaiho et al., 1989). Fig. 1 A shows immunoprecipitation of the metabolically labeled chimeric receptor from serum-starved cells of the clone NEN37 expressing the chimeric receptor and a comparison with receptor immunoprecipitation from neomycin-resistant control cells (NN), NEN37, N6, and NT12 cells as well as anti-EGF-R-precipitates from the C125 cells. Note that the neu oncogene-transformed NT12 cells express smaller amounts of receptor polypeptides than the other receptor transfectants. B, After metabolic labeling overnight, the cells were stimulated with 25 nM EGF (for 2 min) or with buffer (0) and lysates were precipitated with anti-neu and antiphosphotyrosine antibodies, as shown.

**The mRNAs of jun Transcription Factors and the Glucose Transporter Are Induced in Response to EGF Stimulation of the Chimeric EGF-R/neu Receptor**

We wanted to test whether the neu tyrosine kinase was capa-
Figure 2. Induction of early growth factor-stimulated mRNAs by EGF-treatment of cells expressing the chimeric EGF-R/neu proto-oncogene. The N6 and NT12 cells expressing the neu proto-oncogene and oncogene, respectively, and the NEN37 cells expressing the EGF-R/neu construct were treated with 5 nM EGF for the indicated periods of time, lysed, and analyzed in Northern hybridization with the c-jun, junB, GT, and ODC cDNA probes, and as a control, with the GAPDH probe. The sizes of the mRNAs are shown on the right in kilobases.

Figure 3. Time course of junB and ODC mRNA induction in the EGF-treated NN and NEN16 cells. The preparation of RNA samples and their analysis with the junB and ODC probes was as shown in Fig. 2. About 8 µg of poly(A)+ RNA was loaded per lane. Note that GAPDH mRNA is enhanced beginning 4 h after the addition of EGF.

Figure 3. Time course of junB and ODC mRNA induction in the EGF-treated NN and NEN16 cells. The preparation of RNA samples and their analysis with the junB and ODC probes was as shown in Fig. 2. About 8 µg of poly(A)+ RNA was loaded per lane. Note that GAPDH mRNA is enhanced beginning 4 h after the addition of EGF.

Figure 3. Time course of junB and ODC mRNA induction in the EGF-treated NN and NEN16 cells. The preparation of RNA samples and their analysis with the junB and ODC probes was as shown in Fig. 2. About 8 µg of poly(A)+ RNA was loaded per lane. Note that GAPDH mRNA is enhanced beginning 4 h after the addition of EGF.
Figure 4. Effect of cycloheximide on junB, GT, and ODC mRNA expression in the NEN37 cells. Growth-arrested NEN37 cells were treated with EGF (5 nM; black columns), cycloheximide (10 μg/ml; grey columns) or with both EGF and CHX (white columns). At the indicated times poly(A)+ RNA was isolated and analyzed by Northern blotting and hybridization with the junB, GT, and ODC probes. The autoradiographic signals were quantitated by scanning densitometry and the results expressed as fold of induction over control.

of junB was maximal during the first half an hour of EGF treatment and had declined at 6 h back to baseline levels, the expression of ODC mRNA was first enhanced at 2 h of EGF stimulation and reached a maximum (a sixfold increase) at 4 h of EGF treatment in the NEN16 cells (expressing ~4 × 10⁶ chimeric receptors/cell), returning thereafter slowly to preinduction levels. In contrast, only about a twofold transient induction of junB and ODC mRNAs was seen in the neomycin-resistant NIH 3T3 cell clone NN treated with EGF. Also the GAPDH mRNA was slightly enhanced beginning 4 h after EGF treatment.

The Induction of Early mRNAs by the neu Tyrosine Kinase Is Independent of Protein Synthesis

To determine whether the induction of the junB, GT, and ODC mRNAs required new protein synthesis we analyzed the effect of cycloheximide (CHX) on the mRNA levels induced by EGF. Serum-starved NEN37 cells were treated with EGF with or without CHX for 0.5, 2, and 4 h. Control experiments were performed with CHX alone. Fig. 4 shows the relative amounts of junB, GT, and ODC mRNAs in the cells quantitated by scanning densitometry. CHX slightly increased the maximal EGF-induced GT levels at 2 h and caused a more striking accumulation of the GT mRNA at 4 h, when the mRNA content was returning to basal levels in cells not treated with CHX. CHX also increased the induction of ODC mRNA levels from 2.5- to 4.5-fold at 2 h and from 6- to 20-fold at 4 h, respectively. EGF also increased junB mRNA in the presence of CHX, although CHX did not further enhance the EGF-induced response at 0.5 h. However, CHX prevented the downregulation of the junB mRNA response at later time points (data not shown).

Increased Synthesis of the Jun and Fos Transcription Factors

The induction of the jun and fos oncogene-encoded polypeptides was analyzed by labeling the EGF-stimulated cells, and for comparison, serum-stimulated cells with 35S-methionine for 45 min beginning 30 min after the addition of the growth factors and immunoprecipitating cell lysates with the jun- and fos-specific peptide antisera. As expected on the basis of the results of mRNA analysis of the neu oncogene-expressing cells, the biosynthesis of the jun protein was not significantly elevated in the neu oncogene-expressing NT11 cells and only slightly increased by EGF in the NIH 3T3 cells, NT11 cells or N6 cells expressing the neu proto-oncogene (Fig. 5). In contrast, EGF increased the jun protein levels of NEN37 cells more than 10-fold, which was of the same order as the stimulation obtained by serum in several experiments. Similar results were obtained for the expression of the fos protein, but the fos immunoprecipitates also contained several other polypeptides, at least one of which comigrated with the jun polypeptides (Fig. 5 B). In conclusion, the cells expressing the chimeric receptor are capable of inducing the fos/jun protein complex, which is essential for the subsequent activation of genes containing the enhancer consensus sequence for jun/AP-1/PEA-1 binding (Chiu et al., 1988).

Activated neu Tyrosine Kinase Is Associated with Increased AP-1/PEA-1 Activity

If the immunoprecipitated fos/jun complex is functional after EGF stimulation, promoters containing the consensus AP-1/PEA-1 binding sequence should be activated in the cells.
Acetylation of the neu tyrosine kinase to induce transactivation of a recombinant CAT expression vector having an AP-1/PEA-1-dependent 12-O-tetradecanoyl-phorbol-13-acetate-responsive element (TRE) by using indicator plasmid transfection into the NEN37 cells. Serum-starved cells were transfected either with the plasmid p5xTREtkCAT containing a fivefold TRE element linked upstream of the thymidine kinase promoter and the CAT gene. Alternatively, a similar plasmid pBLCAT2 lacking the TRE sequences was used (Angel et al., 1987). The luciferase plasmid pRSVL was cotransfected with the reporter recombinants pBLCAT2 and p5xTREtkCAT as an internal control for variations in transfection efficiency of different cell clones. 40 h after transfection part of the transfected cells were treated with 10 nM EGF or 100 nM TPA for 8 h, after which cell extracts were prepared and assayed for CAT activity. CM and AC indicate unacetylated and acetylated forms of the [14C]-labeled chloramphenicol, respectively.

(Chiu et al., 1988; Rauscher III et al., 1988). We examined the ability of the neu tyrosine kinase to induce transactivation of a recombinant CAT expression vector having an AP-1/PEA-1-dependent 12-O-tetradecanoyl-phorbol-13-acetate-responsive element (TRE) by using indicator plasmid transfection into the NEN37 cells. Serum-starved cells were transfected either with the plasmid p5xTREtkCAT containing a fivefold TRE element linked upstream of the thymidine kinase promoter and the CAT gene. Alternatively, a similar plasmid pBLCAT2 lacking the TRE sequences was used (Angel et al., 1987). The luciferase plasmid pRSVL was cotransfected with the reporter recombinants pBLCAT2 and p5xTREtkCAT as an internal control for variations in transfection efficiency of different cell clones. 40 h after transfection part of the transfected cells were treated with 10 nM EGF or 100 nM TPA for 8 h, after which cell extracts were prepared and assayed for luciferase and CAT activities (Gorman et al., 1982; de Wet et al., 1987). Similar levels of luciferase activity were obtained from the NEN and NT cells transfected simultaneously with the same DNA precipitate, suggesting that the transfection efficiency did not differ significantly between these cells (data not shown). However, comparisons of CAT activity between the cells were normalized to luciferase activities, where small variation occurred. An ∼2.5-fold increase in CAT activity was obtained in NEN37 cells stimulated either with EGF or TPA, when compared with the CAT activity in untreated cells from the same transfections (Fig. 6). Interestingly, both of the two neu oncogene-expressing cells tested (NT8 and NT12) showed a high basal level of AP-1/PEA-1 activity (about 4-fold enhanced), which was insensitive to both EGF and TPA stimulation (Fig. 6, and data not shown).

Stimulation of Glucose Transport

Stimulation of glucose transport provides a sensitive way of analyzing growth factor responses in cells (Martin et al., 1971). We tested the activity of the glucose transporter by measuring the rate of uptake of 2-DOG into EGF-treated cells. The cells were growth-arrested by placing the nearly confluent cultures in medium supplemented with 1% FCS for 48 h, after which the cells were treated either with EGF or dialyzed FCS. After a 2 h exposure to EGF, the NEN37 cells expressing the EGF-R/neu receptors showed markedly increased rates of 2-DOG uptake (two- to threefold increase during the first 8 h), whereas the EGF-treated N6 and NT11 cells displayed very little change of 2-DOG transport throughout the experiment (Fig. 7). In the CI25 cells, which express similar levels of EGF receptors, the 2-DOG uptake rate was linearly increased for up to threefold after 8 h treatment with EGF or serum. The uptake was stimulated by serum also in the other cell clones, although the induction was only about twofold in neu-oncogene expressing NT11 cells, which showed a constitutively accelerated rate of glucose transport (Fig. 7, legend), characteristic for oncogenically transformed cells (Flier et al., 1987).

ODC Is Stimulated by the Activated neu Tyrosine Kinase

Measurement of ODC activity from cell lysates after various periods of EGF stimulation showed that while the uninduced levels of ODC activity were similarly reduced in starved NEN37 cells expressing the EGF-R/neu chimera and in control cells, EGF increased ODC activity considerably only in the EGF-R/neu receptor-expressing cells (Fig. 8). However, a very small and transient increase of the ODC activity was also observed in the EGF-treated control cells. This increase is not apparent in Fig. 8 because of the scale of the ODC activity. In NEN37 cells that were starved for serum for 2 d the activity of ODC was ∼60-fold increased (from 0.09 to 5.4 nmol/mg protein/h) 2 h after EGF stimulation and further stimulated 70-fold (from 0.1 to 6.8 nmol/mg protein/h) and 300-fold (from 0.09 to 26.4 nmol/mg protein/h) at 9 h and 24 h, respectively. When the serum-starvation of cells was reduced to 24 h, the EGF-induction of ODC followed a much more rapid kinetics, with the maximal activity level reached displayed very little change of 2-DOG transport throughout the experiment (Fig. 7). In the CI25 cells, which express similar levels of EGF receptors, the 2-DOG uptake rate was linearly increased for up to threefold after 8 h treatment with EGF or serum. The uptake was stimulated by serum also in the other cell clones, although the induction was only about twofold in neu-oncogene expressing NT11 cells, which showed a constitutively accelerated rate of glucose transport (Fig. 7, legend), characteristic for oncogenically transformed cells (Flier et al., 1987).
kinase and EGF-R kinase activities that are controlled by ligand binding and that the neu proto-oncogene and oncogene-encoded kinases are not affected by EGF in the control cell clones.

In NIH 3T3 cells expressing the chimeric EGF-R/neu receptor the jun transcription factor mRNAs are enhanced within 30 min after addition of EGF. These genes, junB and c-jun encode protein components of the transcription factor AP-1/PEA-1 (see Curran and Franza, 1988). The EGF-treated cells contain the typical fos/jun transcription factor complex as shown by metabolic labeling and immunoprecipitation ~1 h after stimulation. This complex can also be seen at similar elevated levels in serum-stimulated NEN cells and control cells, but it is not precipitated from the EGF-treated control cells, including cells transformed by the neu oncogene.

The fos/jun complex has been shown to bind tightly to the TRE enhancer DNA elements and to activate transcription of promoters under their influence (Angel et al., 1987, 1988a; Chiu et al., 1988). Interestingly, the fos/jun complex has also autostimulatory and inhibitory properties on the expression of the c-fos and c-jun genes themselves (Angel et al., 1988b; Sassone-Corsi et al., 1988). We show evidence for an increased AP-1/PEA-1 transcription factor activity in the EGF-treated cells expressing the chimeric receptor by use of a recombinant 5xTRE-CAT vector and transient expression assays. The effect of EGF measured at 8 h of stimulation was comparable to the degree of induction by TPA and to the activity present in unstimulated neu oncogene-expressing cells. It is possible that the increase in the amount of the fos/jun complex, induced by the ligand activation of the neu tyrosine kinase, is capable of activating the subsequent set of genes, whose expression is dependent on the synthesis of novel proteins and can therefore be classified as "early" growth factor-induced genes. However, the reason for the high constitutive activity of a TRE element in transformed cells remains unknown. Our experiments with the ras and neu oncogenes suggest that elevated jun and fos mRNA and protein expression may not be responsible for this difference (Sistonen et al., 1989; our present study). Possibly, the fos protein might be modified by constitutive posttranslational phosphorylation subsequent to the mutational activation of the neu tyrosine kinase and the modified fos/jun complex then could maintain several genomic responses. On the other hand, we have not yet analyzed the possibility that these proteins would be more stable in the transformed cells.

Since an accelerated rate of glucose transport is among the most characteristic biochemical markers of growth stimulation and the transformed phenotype, we decided to use the analysis of the GT gene expression to study the pattern and kinetics of gene activation in our EGF dependent growth and transformation model system. cDNAs encoding the human hepatoma (Mueckler et al., 1985) and the rat brain (Birnbaum et al., 1986) GT have been used to demonstrate that elevated levels of GT mRNA are associated with an accelerated rate of glucose transport in oncogenically transformed cells (Birnbaum et al., 1987). In the case of cells transformed with v-src or activated c-ras oncogenes, it was suggested that the signal transduction mechanisms activated by the oncogene would be associated with the elevated GT mRNA expression (Flier et al., 1987). In accordance with these results, the increased rate of glucose transport in the neu

Discussion

Our results show that the activated neu tyrosine kinase induces changes of transcriptional, nutrient transport and enzymatic activities typical for cell growth activation and cell cycle progression of growth factor-stimulated cells. These effects mimic those induced by EGF in EGF-receptor expressing cells (DiPasquale et al., 1978; Quantin and Breathnach, 1988; Hiraki et al., 1988). One of the earliest changes in gene expression induced by the activation of the neu tyrosine kinase is the induction of the mRNA and protein for the jun transcription factors, followed by an increase in the expression of the GT and ODC mRNAs. Interestingly, all three mRNAs were induced in the presence of the protein synthesis inhibitor CHX, indicating that these genes are stimulated by preexisting factors in the responding cells. Possibly, such factors become modified by posttranslational mechanisms, such as protein phosphorylation and become capable of stimulating the transcription of the set of immediate early and early responding genes.

Our immunoprecipitation results indicated that cells of the NEN37 clone expressing the chimeric EGF-R/neu protein at ~4 × 10⁶ receptors/cell as well as cells of the clone CI25 expressing the EGF-R at similar levels reacted to EGF stimulation by a rapid tyrosine phosphorylation of the receptors. In contrast, EGF had no effect on the antiphosphotyrosine immunoprecipitation of neu proteins from cells of the N6 or NT 12 clones expressing the neu proto-oncogene and oncogene, respectively. These results establish that the cells clones used in this study express the EGF-R/neu tyrosine
oncogene-transformed NT cells correlated with significantly elevated GT mRNA levels.

Recently, it has also been shown that serum and the purified growth factors EGF, PDGF and FGF regulate the glucose transport system at a transcriptional level (Hiraki et al., 1988; Rollins et al., 1988). The GT mRNA induction in the NEN cells expressing the EGF-R/neu receptor was independent of protein synthesis, as has been found using other cells and EGF and PDGF receptor-ligand systems (Hiraki et al., 1988; Rollins et al., 1988). The time course of EGF-induced GT mRNA increase correlates with the actual increase of glucose transport measured by the uptake of 2-DOG, although the mRNA levels were already declining at 4 h of treatment, when the 2-DOG transport rate was still rising. The maximal enhancement of the GT mRNA was about sixfold, whereas the maximal transport rate was threefold over unstimulated values. This parallels the results of Rollins et al. (1988) and supports the hypothesis on the existence of translational and posttranslational controls of GT expression.

We have previously shown that in NIH 3T3 cells, where expression of the activated c-Ha-ras oncogene is induced from the human heat shock promoter 70 the onset of synthesis of p21+Ha-ras oncprotein is rapidly followed by elevated mRNA levels of the junB, c-jun, GT and ODC genes (Sistonen et al., 1989). Our present results show that the neu tyrosine kinase is also capable of enhancing the expression of these mRNAs, with jun mRNA rising first and the GT and ODC mRNAs thereafter. It has previously been shown that the mitogenic induction of ODC mRNA results, at least partly, from increased transcription of the ODC gene (Katze and Kahana, 1987). The ODC activity follows these changes, but the timing of the peak of ODC activity after EGF stimulation is dependent on the length of prior cell starvation, the dosage of EGF, and the number of receptors on the responding cells. It is of interest that the maximal ODC activities stimulated by EGF and serum in the NEN37 cells are of similar magnitude and closely correspond to the constitutive ODC activity of the neu oncogene-transformed cells. Further, the induction of ODC by EGF in the chimeric EGF-R/neu expressing cells precedes by several hours their morphological transformation. All these results are consistent with the view that ODC is expressed during the G1 period of the cell cycle, and that the length of the lag period depends on the state of the cells in the G1/G0 phase of the cell cycle before cell stimulation. Thus, this study further strengthens our earlier suggestions based on the c-Ha-ras oncogene-transformed cells (Sistonen et al., 1987; Hulttii et al., 1988) that a deregulated expression of ODC is intimately associated with cell transformation and that a high constitutive activity of ODC is typical for stably transformed cells.

The neu oncogene is activated by a point mutation exchanging glutamic acid for valine in the transmembrane domain of the receptor (Bargmann et al., 1986b). However, it is not known how the neu oncprotein transforms cells. Enhanced tyrosine kinase activity and an increased phosphotyrosine content have been reported for the neu oncprotein in rat cells (Bargmann and Weinberg, 1988a,b; Stern et al., 1986; 1988). The half-life of the oncprotein is also shorter than the half-life of the proto-oncogene-encoded neu protein (Stern et al., 1988), suggesting that the oncprotein undergoes a more rapid rate of internalization and is also targeted to enhanced degradation in lysosomes as proposed for the EGF-R (Schlessinger, 1988). This view is consistent with the recent model for the effects of the activating point mutation of the neu oncprotein, which may greatly increase the rate of receptor dimerization, normally occurring only after ligand stimulation of the neu proto-oncogene-encoded receptor (Sternberg and Gullick, 1989). Our chimeric EGF-R/neu receptor allows at least a tentative model for comparison of the biochemistry and genomic effects of the ligand- and oncogenically activated neu receptors. The present study indicates that both types of receptor activation lead to similar biochemical changes typical for growth factor-stimulated and transformed cells. Interesting differences also exist, as is shown here for the activation of the fos/jun transcription factor complex in the presence and absence of an increase of the corresponding protein components in ligand-stimulated and constitutively neu-transformed cells. The further analysis of such differences will undoubtedly shed light on the pathways of growth factor signal transduction and their deregulations in transformed cells.

We thank Drs. Peter Angel, Olli Jänne, Daniel Nathans, Ora Rosen, Suresh Subramani, and Robert Weinberg for molecular clones, Dr. Peter K. Vogt for antibodies, and Kirsti Mänttäri, Elina Roimaa, and Anne Aronta for technical help.

This work was financed by the Academy of Finland, the Finnish Cancer Organizations, The Finnish Pension and Insurance Companies, the Sigrid Juselius Foundation, and the Research and Science Foundation of Farmos, Finland.

Received for publication 14 March 1989 and in revised form 20 June 1989.

References

Almendral, J. M., D. Sommer, H. Macdonald-Bravo, J. Barchardt, J. Perera, and R. Bravo. 1988. Complexity of the early genetic response to growth factors in mouse fibroblasts. J. Cell. Biol. 107:2140–2148.
Angel, P., E. A. Allegretto, S. T. Okino, K. Hattori, and W. J. Boyle. 1988a. Oncogene jun encodes a sequence-specific trans-activator similar to AP-1. Nature (London). 332:166–170.
Angel, P., K. Hattori, T. Smeal, and M. Karin. 1988b. The jun proto-oncogene is positively autoregulated by its product. J. Biol. Chem. 263:875–885.
Angel, P., M. Imagawa, R. Chiu, B. Stein, R. J. Imbra, H. J. Rahmendorf, C. Jonat, P. Herrlich, and M. Karin. 1987. Phorbol ester-inducible genes contain a common cis element recognized by a TPA-modulated trans-acting factor. Cell 49:729–739.
Bargmann, C. I., and R. A. Weinberg. 1988a. Oncogenic activation of the neu-encoded receptor protein by point mutation and deletion. EMBO (Eur. Mol. Biol. Organ.) J. 7:2043–2052.
Bargmann, C. I., and R. A. Weinberg. 1988b. Increased tyrosine kinase activity associated with the protein encoded by the activated neu oncogene. Proc. Natl. Acad. Sci. USA. 85:5394–5398.
Bargmann, C. I., M.-C. Hung, and R. A. Weinberg. 1986a. The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature (London). 319:226–230.
Bargmann, C. I., M.-C. Hung, and R. A. Weinberg. 1986b. Multiple independent activators of the neu oncogene by a point mutation altering the transmembrane domain pf p185. Cell. 45:649–657.
Birnbaum, M. J., H. C. Haspel, and O. M. Rosen. 1986. Cloning and characterization of a cDNA encoding the rat brain glucose-transporter protein. Proc. Natl. Acad. Sci. USA. 83:5784–5788.
Birnbaum, M. J., H. C. Haspel, and O. M. Rosen. 1987. Transformation of rat fibroblasts by FSV rapidly increases glucose transporter gene transcription. Science (Wash. DC). 235:1495–1498.
Bohmann, D., T. J. Bos, A. Admon, T. Nishimura, P. K. Vogt, and R. Tjian. 1987. Human proto-oncogene c-jun encodes a DNA binding protein with structural and functional properties of transcription factor AP-1. Science (Wash. DC). 238:1386–1392.
Chiu, R., W. J. Boyle, J. Meek, T. Smeal, T. Hunter, and M. Karin. 1988. The c-fos protein interacts with c-Jun/AP-1 to stimulate transcription of AP-1 responsive genes. Cell. 54:541–552.
Curran, T., and B. R. Franzan, Jr. 1988. Fos and Jun: the AP-1 connection. Cell. 55:395–397.
de Wet, J. R., K. V. Wood, M. DeLuca, D. R. Helsinki, and S. Subramani. 1987. Firefly luciferase gene: structure and expression in mammalian cells. Mol. Cell. Biol. 7:725–737.
DiPasquale, A., D. White, and J. McGuire. 1978. Epidermal growth factor stimulates pуревуск transport and ornithine decarboxylase activity in cultivated human fibroblasts. Exp. Cell Res. 116:317–323.

Flier, J. S., M. M. Mueckler, P. Usher, and H. F. Lodish. 1987. Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes. Science (Wash. DC). 235:1492–1495.

Fort, Ph., L. Marty, M. Pichaczky, S. El Sibouaty, Ch. Dani, Ph. Jeantet, and J. M. Blanchard. 1985. Various rat adult tissues express only one major mRNA species from the glyceraldehyde-3-phosphate-dehydrogenase multigene family. Nucleic Acids Res. 13:1431–1442.

Gorman, C. M., L. F. Moffat, and B. H. Howard. 1982. Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells. Mol. Cell. Biol. 2:1044–1051.

Graham, F. L., and A. J. van der Eb. 1973. A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology. 52:456–467.

Greenberg, M. E., and E. B. Ziff. 1984. Stimulation of 3T3 cells induces transcription of the c-fos proto-oncogene. Nature (Lond.). 311:433–438.

Harrington, C.-H., and B. Westermark. 1984. Growth factors: mechanism of action and modulated events regulating cellular proliferation. Methods Enzymol. 147:400–407.

Heldin, C.-H., and B. Westmark. 1984. Growth factors: mechanism of action and relation to oncogenes. Cell. 37:9–20.

Hiraki, Y., O. M. Rosen, and J. M. Birnbaum. 1988. Growth factors rapidly stimulate putrescine transport and ornithine decarboxylase activity in cultured cells. J. Biol. Chem. 263:433–438.

Heldin, C.-H., and B. Westmark. 1984. Growth factors: mechanism of action and relation to oncogenes. Cell. 37:9–20.

Hiraki, Y., O. M. Rosen, and J. M. Birnbaum. 1988. Growth factors rapidly induce expression of the glucose transporter gene. J. Biol. Chem. 263:13655–13662.

Hölttä, E., L. Sistonen, and K. Altitalo. 1988. The mechanisms of ornithine decarboxylase deregulation in c-Ha-ras oncogene-transformed NIH 3T3 cells. J. Biol. Chem. 263:4500–4507.

Hudziak, R. M., J. Schlessinger, and A. Ullrich. 1987. Increased expression of the putative growth factor receptor p185src causes transformation and tumorigenesis of NIH 3T3 cells. Proc. Natl. Acad. Sci. USA. 84:7159–7163.

Jänne, O. A., K. K. Kontula, V. V. Isomaa, and C. W. Bardin. 1984. Ornithine decarboxylase mRNA in mouse kidney: a low abundance gene product regulated by androgens with rapid kinetics. Ann. NY Acad. Sci. 438:72–84.

Katz, A., and C. Kahana. 1987. Transcriptional activation of mammalian ornithine decarboxylase during stimulated growth. Mol. Cell. Biol. 7:2641–2643.

Laemmli, U. K. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (Lond.). 227:680–685.

Lamp, W. W., P. Wamsley, P. Sassone-Corsi, and I. M. Verma. 1988. Induction of proto-oncogene JUN/AP-1 by serum and TPA. Nature (Lond.). 334:629–631.

Lau, L. F., and D. Nathans. 1987. Expression of a set of growth-related immediate early genes in BALB/c 3T3 cells: Coordinate regulation with c-fos or c-myc. Proc. Natl. Acad. Sci. USA. 84:1182–1186.

Lehtola, L., H. Lehväslaiho, L. Sistonen, K. Saksela, and K. Altitalo. 1989. EGF stimulation of a chimeric EGFR/neu protein in NIH/3T3 cells induces receptor downregulation, induction of morphological changes and increased DNA-synthesis. Growth Factors. In press.

Lehväslaiho, H., L. Lehtola, L. Sistonen, and K. Altitalo. 1989. A chimeric EGF-R/neu proto-oncogene allows EGF to regulate neu tyrosine kinase and cell transformation. EMBO (Eur. Mol. Biol. Organ.). J. 8:159–166.

Martin, G. S., Venuta, S., Weber, M., and H. Rubín. 1971. Temperature-dependent alterations in sugar transport in cells infected by a temperature-sensitive mutant of Rous sarcoma virus. Proc. Natl. Acad. Sci. USA. 68:2739–2741.

Mueckler, M., C. Caruso, S. A. Baldwin, M. Panico, I. Blench, H. R. Morris, W. J. Allard, G. E. Lienhard, and H. F. Lodish. 1985. Sequence and structure of a human glucose transporter. Science (Wash. DC). 229:941–945.

Quantin, B., and R. Breathnach. 1988. Epidermal growth factor stimulates transcription of the c-jun proto-oncogene in rat fibroblasts. Nature (Lond.). 334:533–539.

Rauscher, F. J., III, L. C. Sambucetti, T. Curran, R. J. Distel, and B. M. Spiegelman. 1988. Common DNA binding site for fos protein complexes and transcription factor AP-1 Cell. 52:471–480.

Rollins, B. J., E. D. Morrison, P. Usher, and J. S. Flier. 1988. Platelet-derived growth factor regulates glucose transporter expression. J. Biol. Chem. 263:16523–16526.

Russell, W. C., C. Newman, and D. H. Williamson. 1975. A simple cytochemical technique for demonstration of DNA in cells infected with mycoplasmas and viruses. Nature (Lond.). 253:461–462.

Ryder, K., and D. Nathans. 1988. Induction of protooncogene c-jun by serum growth factors. Proc. Natl. Acad. Sci. USA. 85:8464–8467.

Ryder, K., L. F. Lau, and D. Nathans. 1988. A gene activated by growth factors is related to the oncogene v-jun. Proc. Natl. Acad. Sci. USA. 85:1487–1491.

Ryseck, R.-P., S. I. Hirai, M. Yaniv, and R. Bravo. 1988. Transcriptional activation of c-jun during the C2/G1 transition in mouse fibroblasts. Nature (Lond.). 334:535–537.

Sassone-Corsi, P., J. Sisson, and I. M. Verma. 1988. Transcription autoregulation of the proto-oncogene fos. Nature (Lond.). 334:314–319.

Schechter, A. L., D. F. Stern, L. Vaidyanathan, S. J. Decker, F. J. A. Drebin, M. I. Greene, and R. A. Weinberg. 1984. The neu oncogene: an erb-B-related gene encoding a 185 000-M subunit, tumour antigen. Nature (Lond.). 312:513–516.

Schlessinger, J. 1988. Signal transduction by allosteric receptor oligomerization. Trends Bio. Sci. 13:443–447.

Schwab, M., K. Altitalo, H. E. Varumus, J. M. Bishop, and D. George. 1983. A cellular oncogene (c-Ki-ras) is amplified, overexpressed, and located within karyotypic abnormalities in mouse adenocarcinoma tumor cells. Nature (Lond.). 303:497–501.

Schwab, M., H. E. Varumus, and J. M. Bishop. 1985. Human N-myc gene contributes to neoplastic transformation of mammalian cells in culture. Nature (Lond.). 316:160–162.

Seki, J., M. K. Owada, N. Sakato, and H. Fuji. 1986. Direct identification of phosphorytrosine-containing proteins in some retrovirus-transformed cells by use of anti-phosphotyrosine antibody. Cancer Res. 46:907–916.

Sistonen, L., J. Keski-Oja, I. Ullmanen, E. Hölttä, B.-J. Wikgren, and K. Altitalo. 1987. Dose effects of transfected c-Ha-ras cDNA oncogene in transformed cell clones. Exp. Cell Res. 168:518–530.

Sistonen, L., E. Hölttä, T. F. Maäskälä, J. Keski-Oja, and K. Altitalo. 1989. The cellular response to induction of the p21 c-Ha-ras src oncogene in transformed cell clones. EMBO (Eur. Mol. Biol. Organ.). J. 8:815–822.

Stern, D. F., P. A. Heffernan, and R. A. Weinberg. 1986. p185, a product of the neu proto-oncogene, is a receptorlike protein associated with tyrosine kinase activity. Mol. Cell. Biol. 6:1729–1740.

Stern, D. F., M. P. Kamps, and H. Cao. 1988. Oncogenic activation of p185src stimulates tyrosine phosphorylation in vivo. Mol. Cell. Biol. 8:3969–3973.

Sternberg, M. J. E., and W. J. Guillick. 1989. Neu receptor dimerization. Nature (Lond.). 339:587.

Vela, T. J., L. Beguinot, W. C. Vass, M. C. Williams, G. T. Merlino, I. Pastan, and D. R. Lowy. 1987. Epidermal growth factor-dependent transformation by a human EGF receptor proto-oncogene. Science (Wash. DC). 238:1408–1410.